Cargando…

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer

Epigenetic mechanisms play an important role in the development and persistence of cancer, and histone deacetylase (HDAC) inhibitors are promising anticancer drugs targeting epigenetic modes. Efficient anticancer drugs for the treatment of castration-resistant prostate cancer (CRPC) are sought, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biersack, Bernhard, Nitzsche, Bianca, Höpfner, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992583/ https://www.ncbi.nlm.nih.gov/pubmed/35582529 http://dx.doi.org/10.20517/cdr.2021.105

Ejemplares similares

Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors
por: Goehringer, Nils, et al.
Publicado: (2021)

Synthetic Small Molecule Modulators of Hsp70 and Hsp40 Chaperones as Promising Anticancer Agents
por: Nitzsche, Bianca, et al.
Publicado: (2023)

Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer
por: Bär, Sofia Isolde, et al.
Publicado: (2022)

Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma
por: Ma, Andi, et al.
Publicado: (2022)

Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
por: Coulter, Jonathan B., et al.
Publicado: (2023)

Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
por: Zhang, Ailin, et al.
Publicado: (2023)

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
por: Wang, Xiaoguang, et al.
Publicado: (2020)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance
por: Jo, Hyein, et al.
Publicado: (2022)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer
por: Armstrong, Cameron M., et al.
Publicado: (2016)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Castration-resistant prostate cancer: potential targets and therapies
por: Parray, Aijaz, et al.
Publicado: (2012)

Synthesis and Anticancer Evaluation of New Indole-Based Tyrphostin Derivatives and Their (p-Cymene)dichloridoruthenium(II) Complexes
por: Oberhuber, Natalie, et al.
Publicado: (2023)

Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
por: Yehya, Amani, et al.
Publicado: (2022)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
por: He, Yundong, et al.
Publicado: (2016)

Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer
por: Moon, Sue Jin, et al.
Publicado: (2021)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
por: Wu, Meng, et al.
Publicado: (2023)

Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
por: Liu, Yuan, et al.
Publicado: (2021)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
por: Liva, Sophia G, et al.
Publicado: (2020)

Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Rana, Zohaib, et al.
Publicado: (2021)

Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
por: Bahmad, Hisham F., et al.
Publicado: (2022)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
por: Lanka, Sree M., et al.
Publicado: (2023)

HDAC Inhibition Impedes Epithelial-Mesenchymal Plasticity and Suppresses Metastatic, Castration-Resistant Prostate Cancer
por: Ruscetti, Marcus, et al.
Publicado: (2015)

Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC
por: Schade, Amy E., et al.
Publicado: (2023)

Ailanthone: a new potential drug for castration-resistant prostate cancer
por: Peng, Shihong, et al.
Publicado: (2017)

Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

New insights for drug resistance in metastatic castration-resistant prostate cancer
por: Kushwaha, Prem Prakash, et al.
Publicado: (2022)

Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer
por: Steinemann, Gustav, et al.
Publicado: (2019)

SOX8 Knockdown Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting the Notch Signaling Pathway
por: Du, Zhongbo, et al.
Publicado: (2022)

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9fq8tltot257lm4q8a5khf0c72